Custom synthesis of organic compounds in milligram to kilogram quantities and has been our core business since the foundation of SYNRYN. Our team of experienced Scientists led by Dr.NARSAIAH has expertise in the custom synthesis of a wide range of small molecules like API, Stable Isotope Labeled Compounds, Chemical Intermediates, Drug Metabolites, Drug analogs, Analytical Standards, reference standards, pharmaceutical impurities, and new patentable scaffolds.We offer a full range of services in custom organic synthesis, accomplishing complex, multi-step syntheses and "difficult to synthesize" chemistry projects. Our compounds are of high purity (>98%) and are well characterised through MS, HPLC and NMR.


SYNRYN PHARMA offers a full range of service in custom organic synthesis. Our scientists are skilled in performing complex, multi-step synthesis and solving difficult chemistry-related problems. Based on our integrated and centralized operation and low overheads, we are able to offer prompt quotations, very competitive prices, high quality products and fast deliveries. Our customers include established pharmaceutical, biotech and drug discovery organizations, research institutions, and chemical distributors


Qualification of the impurities is the process of acquiring and evaluating data that establishes biological safety of an individual monograph or dug Substance. Impurity standards thus revealing the need and scope of Impurity profiling of drugs in Pharmaceutical Research We have subject matter experts, who are engaged in the synthesis of impurities and metabolites of active pharmaceutical ingredients which include antibiotics, steroids, chiral, achiral drugs and deuterated compounds. The subject matter experts possess core skills in reaction design, complex synthesis, purification, analysis and characterization.


In addition to its wide range of existing standards, SYNRYN has considerable expertise in the identification and synthesis of new and challenging degradants and impurities. SYNRYN can provide expert advice on the mechanism of degradant formation and advise on modifications to formulations to reduce their levels. We can synthesise multigram quantities of degradants for toxicity testing and assist with your product development.


SYNRYN understands the needs of industry. Our certified standards are shipped with a Certificate of Analysis, MSDS and all the required documentation to ensure statutory domestic and international reputations. Our standards are of high purity, scientifically characterized. Our laboratory and quality systems have successfully passed audits by major pharmaceutical companies, four largest manufacturers among them.

We have over 8500 standards available in ready stock. Each Impurity Standard, Working standard is provided with its Certificate of Analysis, HPLC, NMR , MASS Spectra etc with interpretation.


Early metabolic evaluation has become pivotal for new drug discovery and lead optimization. SYNRYN staff has great experience enabling us to provide complete in vitro and in vivo metabolism data packages for new chemical entities (NCEs), as well as older products requiring updated information. Our laboratories consist of state-of-the-art instrumentation and our scientist use the best methodologies to provide ADME Package that can accelerate drug discovery and optimization time, thereby conserving resources for future clinical development. Our expertise in the field of drug metabolism allows us to provide optimal results to our clients in the most efficient and cost effective manner.


Deuterium offers a subtle, but sometimes powerful, medicinal chemistry tool little attention to Selective deuteration retains biochemical potency and selectivity, and provides substantial benefits to the overall pharmacological profile of the resulting compounds. When applied to compounds with well-understood therapeutic utility, selective deuteration can be a unique risk-reduced approach to creating new chemical entity drugs that address significant unmet medical needs. Over the time, more deuterium-containing compounds entering clinical evaluations it appears increasingly likely that the approach will succeed in producing new medicines for incurable diseases.